Key Takeaways CVS adds Wegovy to Caremark formularies while removing Zepbound to balance costs and access. The move supports CVS' Weight Management program, pairing GLP-1 with lifestyle coaching. CVS shares are up 48.8% YTD, trading at a forward P/S of 0.21X versus the industry average of 0.40X.For CVS Health (CVS) , the key to building customer trust is to enhance access to life-changing medications and also make them affordable. Beginning July 1, the company’s Pharmacy Benefit Manager (“PBM”), CVS Carem ...

Company Overview - Mobile-health Network Solutions is a leading MedTech innovator ranked 41 in the Financial Times 2024 listing of 500 High-growth Asia-Pacific Companies [4] - The company is the first telehealth provider from the Asia-Pacific region to be listed in the US, offering personalized and reliable medical attention globally [4] - Its platform enables healthcare providers to reach users through virtual clinics without start-up costs, connecting them to a global network of peer-to-peer support groups and partners [4] Share Repurchase Program - The Board of Directors has approved a share repurchase program to buy back up to 214,000 Class A Ordinary Shares, effective immediately for one year [1] - The program reflects the Board's confidence in the company's long-term growth prospects and is seen as a compelling use of capital at current share prices [2] - Repurchases may occur through various means, including open market transactions and privately negotiated transactions, depending on market conditions and regulatory requirements [2][3] Market Position and Strategy - The company believes its current share price does not reflect its intrinsic value or the strength of its fundamentals [2] - The share repurchase program does not obligate the company to repurchase a specific number of shares and can be modified or terminated at the company's discretion [3]

Core Insights - LifeMD, Inc. has launched a limited-time introductory bundle for new self-pay patients, offering Wegovy at a discounted price of $199 along with access to its virtual weight management program for a total first-month cost of $299 [1][2] - The collaboration with Novo Nordisk enhances LifeMD's ability to provide branded GLP-1 medications through a fully integrated care experience, catering to the increasing number of self-pay patients seeking FDA-approved treatments [2][4] - The program will cost $599 per month starting from the second month, with no long-term commitment required [3] Company Overview - LifeMD is a leading provider of virtual primary care services, offering telemedicine, laboratory, and pharmacy services across more than 200 conditions, including weight management [6] - The company utilizes a vertically integrated platform, which includes a 50-state medical group and national diagnostic lab partnerships, to ensure a seamless experience from consultation to ongoing support [4][6] Product Offering - Wegovy is the first GLP-1 therapy approved in the U.S. for chronic weight management and cardiovascular risk reduction in adults with obesity, available in an injector pen by prescription for eligible LifeMD patients [5]

Justin Schreiber, Chairman and CEO of LifeMD, said, "LifeMD had an outstanding first quarter that demonstrated the power of our platform, the need for our services and the accelerated growth trajectory of the business as we achieved our first-ever quarter of GAAP profitability well ahead of expectations. During the quarter we expanded across all service areas, and the performance of our weight management program underscored our success as it is now expected to exceed top- and bottom-line expectations for th ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD’s virtual care platform. LifeMD’s weight management program is one of the fastest-growing cash-pay offerings in the countr ...

Company Overview - Mobile-health Network Solutions (MNDR) is a pioneering MedTech company focused on enhancing human connection through technology [1] - The company is ranked 41 in the Financial Times 2024 listing of 500 High-growth Asia-Pacific Companies and is the first telehealth provider from the Asia-Pacific region to be listed in the US [4] - MNDR offers a range of telehealth solutions including teleconsultation services, prescription fulfillment, and personalized services such as weight management programs and gender-specific care [4] Upcoming Events - MNDR will present at the Centurion One Capital 8th Annual Growth Conference from March 3rd to March 6th, 2025, at the Four Seasons Hotel in Toronto [1][3] - Co-founders and co-CEOs, Dr. Tung Yeng Siaw and Dr. Rachel Teoh, are scheduled to present on March 6th, 2025, focusing on the company's latest AI technology innovations [2] - The presentation will include the newly deployed AI Agent platform aimed at improving healthcare providers' workflow efficiency [2] Industry Context - The telehealth solutions industry is experiencing growth, with MNDR positioned to capitalize on this trend through its innovative technology and services [4] - Centurion One Capital, the investment banking firm hosting the conference, is dedicated to supporting the growth of companies in North America, indicating a favorable environment for investment in the sector [5][6]